MX2023007609A - Métodos para mejorar la terapia génica no viral. - Google Patents
Métodos para mejorar la terapia génica no viral.Info
- Publication number
- MX2023007609A MX2023007609A MX2023007609A MX2023007609A MX2023007609A MX 2023007609 A MX2023007609 A MX 2023007609A MX 2023007609 A MX2023007609 A MX 2023007609A MX 2023007609 A MX2023007609 A MX 2023007609A MX 2023007609 A MX2023007609 A MX 2023007609A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- subject
- gene therapy
- viral gene
- need
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063130105P | 2020-12-23 | 2020-12-23 | |
| PCT/US2021/073084 WO2022140788A1 (en) | 2020-12-23 | 2021-12-22 | Methods of enhancing non-viral gene therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023007609A true MX2023007609A (es) | 2023-10-17 |
Family
ID=82158434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023007609A MX2023007609A (es) | 2020-12-23 | 2021-12-22 | Métodos para mejorar la terapia génica no viral. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240074986A1 (https=) |
| EP (1) | EP4267253A4 (https=) |
| JP (1) | JP2024501284A (https=) |
| CN (1) | CN116964207A (https=) |
| AU (1) | AU2021410086A1 (https=) |
| CA (1) | CA3206000A1 (https=) |
| MX (1) | MX2023007609A (https=) |
| WO (1) | WO2022140788A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023122062A1 (en) * | 2021-12-21 | 2023-06-29 | Cornell University | Methods for enhanced nucleic acid delivery |
| WO2024054901A1 (en) * | 2022-09-09 | 2024-03-14 | Spark Therapeutics, Inc. | Piperazine compounds |
| EP4583861A1 (en) * | 2022-09-09 | 2025-07-16 | Spark Therapeutics, Inc. | Enhancing non-viral dna delivery and expression |
| WO2025096940A1 (en) * | 2023-11-01 | 2025-05-08 | Spark Therapeutics, Inc. | Lipid compounds |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140141065A1 (en) * | 2012-11-19 | 2014-05-22 | Discovery Genomics, Inc. | Method to achieve extended expression of dna infused into liver |
| WO2019018640A1 (en) * | 2017-07-21 | 2019-01-24 | Novartis Ag | POSOLOGICAL REGIMES FOR ANTI-GITREN ANTIBODIES AND USES THEREOF |
| WO2019226650A1 (en) * | 2018-05-23 | 2019-11-28 | Modernatx, Inc. | Delivery of dna |
| EP3934700A4 (en) * | 2019-03-06 | 2022-12-14 | Generation Bio Co. | NON-ACTIVE LIPID NANOPARTICLES WITH CAPSID-FREE, NON-VIRAL DNA |
-
2021
- 2021-12-22 WO PCT/US2021/073084 patent/WO2022140788A1/en not_active Ceased
- 2021-12-22 JP JP2023538718A patent/JP2024501284A/ja active Pending
- 2021-12-22 AU AU2021410086A patent/AU2021410086A1/en active Pending
- 2021-12-22 CN CN202180094347.5A patent/CN116964207A/zh active Pending
- 2021-12-22 CA CA3206000A patent/CA3206000A1/en active Pending
- 2021-12-22 EP EP21912293.4A patent/EP4267253A4/en active Pending
- 2021-12-22 US US18/258,981 patent/US20240074986A1/en active Pending
- 2021-12-22 MX MX2023007609A patent/MX2023007609A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3206000A1 (en) | 2022-06-30 |
| EP4267253A1 (en) | 2023-11-01 |
| AU2021410086A1 (en) | 2023-07-06 |
| JP2024501284A (ja) | 2024-01-11 |
| EP4267253A4 (en) | 2024-09-04 |
| US20240074986A1 (en) | 2024-03-07 |
| WO2022140788A1 (en) | 2022-06-30 |
| AU2021410086A9 (en) | 2024-10-03 |
| CN116964207A (zh) | 2023-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023007609A (es) | Métodos para mejorar la terapia génica no viral. | |
| Ryter et al. | Targeting heme oxygenase-1 and carbon monoxide for therapeutic modulation of inflammation | |
| CA2703234C (en) | An inhalable dry powder formulation comprising glp-1 for use by pulmonary inhalation | |
| WO2022195074A3 (en) | Gene therapy composition and treatment of right ventricular arrhythmogenic cardiomyopathy | |
| Hu et al. | Lentivirus-mediated transfer of MMP-9 shRNA provides neuroprotection following focal ischemic brain injury in rats | |
| MX2024000049A (es) | Degradador de tirosina cinasa y mutante de bruton, composicion y aplicacion del mismo. | |
| DK0661987T3 (da) | Morphogeninduceret leverregeneration | |
| WO2003063780A3 (en) | Therapeutic composition for treatment of cancer by arginine depletion | |
| EP4151210A3 (en) | Pyridine-carboline derivatives as mchr1 antagonists for use in therapy | |
| WO2019231725A3 (en) | Treatment of gaucher disease | |
| WO2022241302A3 (en) | Gene therapy constructs and methods for treatment of hearing loss | |
| JOP20190019B1 (ar) | تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH) | |
| MX2022008412A (es) | Variantes de enzima que agotan metiltioadenosina/adenosina mejorada humana para terapia de cancer. | |
| WO2021242794A3 (en) | Living cells engineered with polyphenol-functionalized biologically active nanocomplexes | |
| WO2021048172A3 (en) | Delivery vehicle for in situ delivering of pharmaceutical agents | |
| MX2024009337A (es) | Citocinas terapeuticas y metodos. | |
| MX2021011289A (es) | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. | |
| PH12022551985A1 (en) | Compositions and methods for delivering pharmaceutically active agents | |
| JOP20170044B1 (ar) | تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو | |
| JP2014502992A (ja) | 癌のための併用療法 | |
| MX2024003241A (es) | Terapia genica con frataxina. | |
| CN116710121A (zh) | 用于治疗实体癌的组合物和方法 | |
| TWI656131B (zh) | Nrf-1蛋白質用以製備治療膀胱癌之藥物的用途 | |
| KR20210039413A (ko) | 암의 치료를 위한 병용 요법 | |
| US12194057B2 (en) | NXTAR-derived oligonucleotides and uses thereof |